Last reviewed · How we verify
SYNB1934
At a glance
| Generic name | SYNB1934 |
|---|---|
| Sponsor | Synlogic |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3) (PHASE3)
- Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria (PHASE2)
- Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SYNB1934 CI brief — competitive landscape report
- SYNB1934 updates RSS · CI watch RSS
- Synlogic portfolio CI